| abstract |
FIELD: organic chemistry. n SUBSTANCE: invention relates to a heterocyclic compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof, in which Q denotes a group of formula (Qa), in which the sign of the sprocket (*) indicates the position of attachment to the rest of the molecule; Y represents -C(O)N(R 4 )-; Z is aryl, selected from phenyl, or heteroaryl, selected from pyrazine, imidazopyridine, pyridine, any of these groups may optionally contain one or two substitutes independently selected from a group comprising halogen, cyano, C 1 -C 6 -alkyl, trifluoromethyl, dihalogen-azetidine, C 1 -C 6 -alkoxy group, difluoromethoxy group, trifluoromethoxy, di(C 1 -C 6 )alkylamino; A 1 denotes C 1 -C 6 -alkyl optionally substituted with -OR a ; A 2 , R 4 , R 12 and R a denote hydrogen; R 11 denotes hydrogen or an amino group; R 13 denotes C 1 -C 6 -alkyl. Invention also relates to a pharmaceutical composition based on the compound of formula (IA). n n n n n EFFECT: obtaining novel pyrazolo[3,4-b]pyridine derivatives useful as inhibitors of phosphatidyl inositol-4-kinase IIIβ activity (PI4KIIIβ). n 11 cl, 39 ex |